Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Pfizer invests in and partners with Oric

by Shi En Kim
December 29, 2022 | A version of this story appeared in Volume 101, Issue 1

 

Pfizer will collaborate with Oric Pharmaceuticals on a Phase 2 study of a small-​molecule multiple myeloma treatment. The drug candidate, ORIC-533, is an inhibitor of the enzyme CD73 and will be deployed in the clinic in combination with a Pfizer antibody. CD73 controls the rate at which extracellular adenosine is produced, and its overexpression is associated with poor prognosis in several cancers, Oric says. Under the deal, Pfizer will make an equity investment in Oric amounting to $25 million.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.